Abstract:Rationale: Bitter taste receptors (TAS2Rs) are abundantly expressed in airway smooth muscle cells (ASMCs), which have been recognized as promising targets for bitter agonists to initiate relaxation and thereby prevent excessive airway constriction as the main characteristic of asthma. However, due to the current lack of tested safe and potent agonists functioning at low effective concentrations, there has been no clinically approved TAS2R-based drug for bronchodilation in asthma therapy. This study thus aimed at exploring TAS2R agonists with bronchodilator potential by BitterDB database analysis and cell stiffness screening. Methods: Bitter compounds in the BitterDB database were retrieved and analyzed for their working subtype of TAS2R and effective concentration. Compounds activating TAS2R5, 10, and 14 at < 100 μM effective concentration were identified and subsequently screened by cell stiffness assay using optical magnetic twisting cytometry (OMTC) to identify the most potent to relax ASMCs. Then the compound identified was further characterized for efficacy on various aspects related to relaxation of ASMCs, incl. but not limited to traction force by Fourier transform traction force microscopy (FTTFM), [Ca2+]i signaling by Fluo-4/AM intensity, cell migration by scratch wound healing, mRNA expression by qPCR, and protein expressing by ELISA. The compound identified was also compared to conventional β-agonist (isoproterenol and salbutamol) for efficacy in reducing cell stiffness of cultured ASMCs and airway resistance of ovalbumin-treated mice. Results: BitterDB analysis found 18 compounds activating TAS2R5, 10, and 14 at < 100 μM effective concentration. Cell stiffness screening of these compounds eventually identified flufenamic acid (FFA) as the most potent compound to rapidly reduce cell stiffness at 1 μM. The efficacy of FFA to relax ASMCs in vitro and abrogate airway resistance in vivo was equivalent to that of conventional β-agonists. The FFA-induced effect on ASMCs was mediated by TAS2R14 activation, endoplasmic reticulum Ca2+ release, and large-conductance Ca2+-activated K+ (BKCa) channel opening. FFA also attenuated lipopolysaccharide-induced inflammatory response in cultured ASMCs. Conclusions: FFA as a potent TAS2R14 agonist to relax ASMCs while suppressing cytokine release might be a favorite drug agent for further development of TAS2R-based novel dual functional medication for bronchodilation and anti-inflammation in asthma therapy.

Bitter Taste Receptors for Asthma Therapeutics

Future bronchodilator therapy: a bitter pill to swallow?

Bitter taste receptors in the wrong place: novel airway smooth muscle targets for treating asthma

Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction

Bitter taste receptor function in asthmatic and nonasthmatic human airway smooth muscle cells

Bitter Taste Receptors: Extraoral Roles in Pathophysiology

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models

Pleiotropic Effects of Bitter Taste Receptors on [Ca2+]i Mobilization, Hyperpolarization, and Relaxation of Human Airway Smooth Muscle Cells

The cellular and molecular basis of bitter tastant-induced bronchodilation

TAS2R activation promotes airway smooth muscle relaxation despite β(2)-adrenergic receptor tachyphylaxis

Tas2R activation relaxes airway smooth muscle by release of Gα t targeting on AChR signaling

New Advances and Potential Therapies for the Treatment of Asthma

Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle

Association between Polymorphisms in Bitter Taste Receptor Genes and Clinical Features in Korean Asthmatics

Can We Find Better Bronchodilators to Relieve Asthma Symptoms?

Therapeutical Measures to Control Airway Tolerance in Asthma and Lung Cancer

G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action

Taste and smell GPCRs in the lung: Evidence for a previously unrecognized widespread chemosensory system

BitterDB database analysis plus cell stiffness screening identify flufenamic acid as the most potent TAS2R14-based relaxant of airway smooth muscle cells for therapeutic bronchodilation

Targeting T2Rs, a feasible approach for natural bitter agents from traditional Chinese medicine modulate ABC transporters to treat respiratory diseases

Analysis of the Expression of Human Bitter Taste Receptors in Extraoral Tissues